Spotlight on nivolumab in the treatment of renal cell carcinoma: Design, development, and place in therapy

Vyshak Alva Venur, Monika Joshi, Kenneth G. Nepple, Yousef Zakharia

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Several tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptors and molecules inhibiting the mammalian target of rapamycin are being used for management of metastatic renal cell carcinoma (mRCC); however, there is still a potential for improvement. Immune checkpoint inhibitors like nivolumab and other PD-1/PD-L1 inhibitors provide an alternative approach for patients with mRCC. In this article, the authors review the safety profile and outcomes of phase 1, 2, and 3 clinical trials of nivolumab in mRCC.

Original languageEnglish (US)
Pages (from-to)1175-1182
Number of pages8
JournalDrug Design, Development and Therapy
Volume11
DOIs
StatePublished - Apr 11 2017

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Fingerprint Dive into the research topics of 'Spotlight on nivolumab in the treatment of renal cell carcinoma: Design, development, and place in therapy'. Together they form a unique fingerprint.

  • Cite this